COMPLETE AND PARTIAL-RESPONSE (CR, PR) IN TREATMENT OF ADVANCED REFRACTORY B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA (B-CLL) USING CAMPATH-1H

被引：0
|
作者：
JANSON, D [1 ]
NISSELHOROWITZ, S [1 ]
SATTLER, M [1 ]
RAI, KR [1 ]
机构：
[1] LONG ISL JEWISH MED CTR,DIV HEMATOL ONCOL,NEW HYDE PK,NY 11042
来源：
BLOOD | 1993年 / 82卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A139 / A139
页数：1
相关论文
共 50 条
  • [11] GENETIC PREDISPOSITION OF AUTOIMMUNE-DISEASE AND B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA (B-CLL)
    SHIRAI, T
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 173 (01): : 133 - 140
  • [12] CYCLOSPORINE-A IN THE TREATMENT OF B-CHRONIC LYMPHOCYTIC-LEUKEMIA (B-CLL)
    BERGUI, L
    GREGORETTI, MG
    CALIGARISCAPPIO, F
    LEUKEMIA, 1994, 8 (07) : 1245 - 1246
  • [13] Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection
    Heider, U
    Fleissner, C
    Zavrski, I
    Jakob, C
    Dietzel, T
    Eucker, J
    Ockenga, J
    Possinger, K
    Sezer, O
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 72 (01) : 64 - 66
  • [14] Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H
    Cortelezzi, Agostino
    Vigano, Mauro
    Zilioli, Vittorio R.
    Fantini, Norma N.
    Pasquini, Maria C.
    Deliliers, Giorgio Lambertenghi
    Colombo, Massimo
    Lampertico, Pietro
    JOURNAL OF CLINICAL VIROLOGY, 2006, 35 (04) : 467 - 469
  • [15] Prognostic value of translocations in B-CELL chronic lymphocytic leukemia (B-CLL)
    Van den Neste, E.
    Robin, V.
    Maerevoet, M.
    Hagemeijer, A.
    Stul, M.
    Constantini, S.
    Robert, A.
    Ferrant, A.
    Michaux, L.
    ACTA CLINICA BELGICA, 2006, 61 (02) : 99 - 99
  • [16] T-cell function in patients with B-cell chronic lymphocytic leukemia (B-CLL) following alemtuzumab (Campath®) or fludarabine treatment.
    Kiaii, S
    Mozaffari, F
    Lundin, J
    Rezvany, R
    Chudhury, A
    Mellstedt, H
    Osterborg, A
    BLOOD, 2004, 104 (11) : 689A - 689A
  • [17] Campath-1H in refractory B-CLL -: Complete remission despite p53 gene mutation.
    Stilgenbauer, S
    Scherer, K
    Kröber, A
    Bullinger, L
    Höchsmann, B
    Mayer-Steinacker, R
    Bunjes, D
    Döhner, H
    BLOOD, 2001, 98 (11) : 771A - 771A
  • [18] Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
    Lundin, J
    Kimby, E
    Björkholm, M
    Broliden, PA
    Celsing, F
    Hjalmar, V
    Möllgård, L
    Rebello, P
    Hale, G
    Waldmann, H
    Mellstedt, H
    Österborg, A
    BLOOD, 2002, 100 (03) : 768 - 773
  • [19] Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Ricci, Francesca
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Morra, Enrica
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 41 - 52
  • [20] Rituximab and Campath-1H combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    BLOOD, 2003, 102 (11) : 361B - 361B
12345